| Literature DB >> 26231116 |
Gail D Sckisel1, Myriam N Bouchlaka1, Arta M Monjazeb2, Marka Crittenden3, Brendan D Curti3, Danice E C Wilkins4, Kory A Alderson4, Can M Sungur1, Erik Ames1, Annie Mirsoian1, Abhinav Reddy1, Warren Alexander5, Athena Soulika6, Bruce R Blazar7, Dan L Longo8, Robert H Wiltrout9, William J Murphy10.
Abstract
Primary T cell activation involves the integration of three distinct signals delivered in sequence: (1) antigen recognition, (2) costimulation, and (3) cytokine-mediated differentiation and expansion. Strong immunostimulatory events such as immunotherapy or infection induce profound cytokine release causing "bystander" T cell activation, thereby increasing the potential for autoreactivity and need for control. We show that during strong stimulation, a profound suppression of primary CD4(+) T-cell-mediated immune responses ensued and was observed across preclinical models and patients undergoing high-dose interleukin-2 (IL-2) therapy. This suppression targeted naive CD4(+) but not CD8(+) T cells and was mediated through transient suppressor of cytokine signaling-3 (SOCS3) inhibition of the STAT5b transcription factor signaling pathway. These events resulted in complete paralysis of primary CD4(+) T cell activation, affecting memory generation and induction of autoimmunity as well as impaired viral clearance. These data highlight the critical regulation of naive CD4(+) T cells during inflammatory conditions.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26231116 PMCID: PMC4770886 DOI: 10.1016/j.immuni.2015.06.023
Source DB: PubMed Journal: Immunity ISSN: 1074-7613 Impact factor: 31.745